Compare EDUC & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | VTGN |
|---|---|---|
| Founded | 1965 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 10.8M |
| IPO Year | 1995 | 2014 |
| Metric | EDUC | VTGN |
|---|---|---|
| Price | $1.35 | $0.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 92.9K | ★ 2.7M |
| Earning Date | 05-19-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,913,600.00 | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $0.20 |
| 52 Week High | $1.84 | $5.14 |
| Indicator | EDUC | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 28.96 | 42.81 |
| Support Level | $1.29 | $0.23 |
| Resistance Level | $1.36 | $0.32 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 12.48 | 37.92 |
Educational Development Corp distributes books and educational products and publications through its PaperPie and EDC Publishing divisions to individual consumers, book, toy and gift stores, libraries and home educators located throughout the United States. The company is the owner and exclusive publisher of Kane Miller children's books; Learning Wrap-Ups, maker of educational manipulatives; and SmartLab Toys, maker of STEAM-based toys and games. It also the exclusive United States Multi-Level Marketing (MLM) distributor of Usborne Publishing Limited (Usborne) children's books. It sell children's books, educational toys and games and other related products. It has two reportable segments: PaperPie and Publishing of which majority of revenue comes from Paperpie.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.